Certainly some previous non‐clinical studies have suggested a role for inflammation in MAPT‐associated FTD,40, 41 so it will be important to investigate other inflammatory biomarkers and whether the change in MAPT mutations is stage‐specific. The gene discussed is MAPT; the disease is frontotemporal dementia.